Charles River Laboratories International (NYSE:CRL) Upgraded at Wall Street Zen

Charles River Laboratories International (NYSE:CRL) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Several other equities analysts have also recently issued reports on CRL. Citigroup upped their price target on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, January 16th. JPMorgan Chase & Co. boosted their price objective on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Barclays upped their target price on Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target for the company in a research note on Monday, December 15th. Ten analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $209.46.

Charles River Laboratories International Stock Up 2.9%

Shares of CRL opened at $189.11 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37. Charles River Laboratories International has a 52 week low of $91.86 and a 52 week high of $228.88. The stock has a market capitalization of $9.31 billion, a price-to-earnings ratio of -121.22, a PEG ratio of 5.51 and a beta of 1.63. The stock has a fifty day moving average of $204.33 and a 200-day moving average of $179.76.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $990.43 million. During the same quarter in the prior year, the firm earned $2.59 EPS. The business’s revenue for the quarter was down .5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. LSV Asset Management raised its holdings in shares of Charles River Laboratories International by 59.8% in the 4th quarter. LSV Asset Management now owns 475,900 shares of the medical research company’s stock worth $94,933,000 after purchasing an additional 178,100 shares during the period. Global Retirement Partners LLC increased its position in Charles River Laboratories International by 3,385.2% in the fourth quarter. Global Retirement Partners LLC now owns 1,882 shares of the medical research company’s stock worth $375,000 after buying an additional 1,828 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Charles River Laboratories International by 1.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 16,058 shares of the medical research company’s stock valued at $3,203,000 after buying an additional 301 shares during the period. North Dakota State Investment Board purchased a new position in shares of Charles River Laboratories International during the 4th quarter valued at $334,000. Finally, Elyxium Wealth LLC purchased a new stake in Charles River Laboratories International in the 4th quarter worth about $46,000. 98.91% of the stock is owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.